A supplier comparison becomes more useful when it separates the questions that matter to the project. Identity documentation, lot traceability, analytical coverage, service reliability and cost should remain visible rather than disappearing into one unexplained score.

FDA's Q8, Q9 and Q10 questions and answers describe risk management and the continuing evaluation of a control strategy. That approach supports a practical principle for research purchasing: focus attention on uncertainties that could change the quality decision. FDA Q8 Q9 Q10 questions and answers

Use evidence states rather than impressions

For each requirement, record whether the evidence is verified, supplied but not independently checked, incomplete or unavailable. Include the source and date. These states are more informative than a checkmark that mixes a seller's assertion with a confirmed fact.

Weighting should follow the experiment's needs. A missing analytical property that could confound the main outcome may matter more than a small price difference. Another project may have different priorities. Make those choices explicit before comparing suppliers so the result is not adjusted to favor a preferred outcome.

Preserve unknowns

A blank field does not prove a supplier is poor, and a full field does not guarantee future performance. Unknowns should lead to focused questions or a proportionate decision about additional review. If two offers cannot be compared on the same basis, say so.

An AXON article can teach this method without publishing unsupported competitor rankings. This piece audits no vendor and claims no operational advantage for AXON. A final procurement decision should be made by the authorized institutional owner using current records and the project's approved criteria. Analytical suitability for a laboratory experiment must also remain separate from clinical safety or product approval.